News Releases Year None2022202120202019201820172016 Date Title Jun 29, 2022 Homology Medicines to Present at Upcoming Conferences on its Gene Editing and Gene Therapy Programs for PKU Jun 13, 2022 Homology Medicines Announces FDA Lifted Clinical Hold on pheNIX Gene Therapy Trial for PKU May 18, 2022 Homology Medicines Presents Details of Optimized HMI-103 Nuclease-Free Gene Editing Candidate Featuring Integrated Liver-Specific Promoter to Maximize Long-Term Expression May 16, 2022 Homology Medicines Reports First Quarter 2022 Financial Results and Recent Highlights May 02, 2022 Homology Medicines Announces Upcoming Presentation on Optimized In Vivo Gene Editing Candidate HMI-103 with First Details of Unique Mechanism of Action at ASGCT Annual Meeting Apr 21, 2022 Homology Medicines Announces Promotion of Albert Seymour, Ph.D., to President Mar 23, 2022 Homology Medicines Reports Fourth Quarter and Full Year 2021 Financial Results and Recent Highlights Mar 10, 2022 Homology Medicines Announces Closing of Deal Leveraging its Internal Process Development and CMC Capabilities Through Newly Formed AAV Manufacturing Innovation Business with Oxford Biomedica Mar 03, 2022 Homology Medicines to Participate in Upcoming Investor Conferences Feb 18, 2022 Homology Medicines Provides an Update on pheNIX Gene Therapy Trial for Adults with PKU Pagination Current page 1 Page 2 Next page next › Last page last » Displaying 1 - 10 of 12